Harley CB, Futcher AB, Greider CW
Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
Customers like you also bought Related products
The only naturally occurring B12 in our diet comes from animal products, the rest is artificially added to foods to try and combat deficiencies Fatigue / lethargic Numbness or tingling in hands or feet Mouth ulcers / cankers Foggy memory Depression Vegetarians, vegans, and infrequent meat eaters
doi: 10.1016/j.jaci.2019.07.044 268 HalkenS
She also notes that tablets typically cost less than injectable formulations, but stresses that patients should be offered the most appropriate medication for them it shouldnt be driven by a financial gain